Gurgaon (Haryana) India - September 13, 2005

Ranbaxy Laboratories Limited (RLL) today announced its entry into the Italian Pharmaceutical market with the launch of Ranbaxy Italia S.P.A., in Milan, Italy, a wholly owned subsidiary of Ranbaxy. The Company is charting an organic growth route for itself and will be introducing high quality generic medicines from its extensive international product portfolio by early 2006.

Commenting on the launch of its Italian operations, Mr. Malvinder Mohan Singh, President, Pharmaceuticals and Executive Director, RLL, said, “We are delighted at the launch of our new subsidiary here. I strongly believe that Generic medicines have an important role to play in serving the priorities of the Government to make healthcare more affordable and accessible to all. We are deeply committed to this task and will soon be introducing a number of products in Italy for the benefit of all patients.”

Ranbaxy’s move helps it to consolidate its presence in the top 5 European pharmaceutical markets while recording its presence in 21 of the 25 EU countries. Italy is ranked as the fourth largest pharmaceuticals market in Europe after Germany, UK and France. The total size of the Pharmaceutical Market in Italy was at US$ 16.5 Bn (Source IMS Dec 2003). With the government encouraging generics to reduce the cost of healthcare, this segment is expected to grow rapidly in the coming years. Additional impetus will come from the expiry of some block- buster drug patents, expected by 2008-2009.

Ranbaxy Laboratories Limited, headquartered in India, is an integrated, research based, international pharmaceutical company producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies. Ranbaxy’s continued focus on R&D has resulted in several approvals in developed markets and significant progress in New Drug Discovery Research. The Company’s foray into Novel Drug Delivery Systems has led to proprietary "platform technologies", resulting in a number of products under development. The Company is serving its customers in over 100 countries and has an expanding international portfolio of affiliates, joint ventures and alliances, ground operations in 44 countries and manufacturing operations in 7 countries.